American & European Parkinson's Disease Patients Can Now Access New Rasagiline (Agilect, Azilect) Drug Treatment From Israel

Share Article

Israel is one of the first nations to approve a new Parkinson's Disease drug called Rasagiline (also called Agilect or Azilect). Now, many American & European patients with the neurodegenerative disease are turning to, Israel's only international mail order pharmacy, to obtain the novel treatment.

After experiencing Pope John Paul II's recent death, caused by his long battle with Parkinson's Disease, many of the 1.5 million U.S. and European patients afflicted by the neurodegenerative condition are turning to Israel to obtain the latest treatment Rasagiline (Agilect, Azilect) to fight it.

Rasagiline was approved by the Israeli Minister of Health on January 4, by the European Commission on February 28, and was launched for sale in Israel in March. It will not be available in most of Europe or the United States until later this year.

Already, (, Israel's only international mail order pharmacy, reports that it has had 80 orders for Rasagiline and is receiving dozens of inquiries about it every day from American and European consumers and their physicians.

"Parkinson Disease patients across the U.S. and Europe are desperate for any new therapy that shows considerable promise," said Avi Fadida, Marketing Manager. "Because Rasagiline will not be available in other countries for several months at the earliest, is one of the first pharmacies in the world to provide the treatment to our international customers."

Fadida said dozens of Parkinson Disease specialists in the United States are currently ordering Rasagiline for their patients. Canadian pharmacies are unable to dispense the drug because it has not yet been approved by Health Canada, Canada's drug regulatory authority.

Rasagiline is sold as a once-daily 1-mg tablet as monotherapy for the treatment of early Parkinson's disease and as an adjunct therapy for more advanced Parkinson's Disease. Rasagiline is a second-generation, irreversible monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine. Dopamine is a substance in the brain needed to facilitate movement.

Its approval was based on the results of studies of more than 1,600 patients showing that Rasagiline monotherapy significantly improves motor symptoms and quality of life in patients with early PD. In addition, its adjunct use in patients with advanced disease significantly reduced "off time" and improved associated motor fluctuations. sells 30 tablets of the 1-mg Rasagiline medication for US$279.

Patients and physicians can learn more about Rasagiline by calling toll free at 1-866-ISRA-BUY(477-2289) or visiting its website at

Parkinson's Disease (PD) is a chronic, progressive neurodegenerative condition. The exact cause of PD is not known and is believed to be multifactorial involving genes, environmental factors and aging. Symptoms include tremor, slowness of movement, stiffness, gait and posture problems. As the disease progresses, symptoms worsen, the patient is likely to experience motor complications. Eventually, the disease impairs the patient's ability to function. PD affects men and women equally, and an estimated four million people worldwide suffer from the disease. The disease typically occurs at a late age, affecting approximately 1 percent of the population over the age of 65.

To learn more about Rasagiline and other Parkinson's Disease treatments and background on the condition, contact the European Parkinson's Disease Association ( and the American Parkinson Disease Association (

Rasgiline was developed based on research by Israeli-based Teva Pharmaceutical Industries, Ltd. and Technion-Israel Institute of Technology. The drug is being developed and marketed in Europe by Teva and H. Lundbeck A/S. The treatment's brand name is "Azilect" in Europe and it will be called "Agilect" in the United States.

Media Contact:

Michael Pirages,

Pirages Communications


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Pirages
Visit website